Skip to main content
. 2018 Dec 11;10:6843–6856. doi: 10.2147/CMAR.S186546

Table S1.

Patient characteristics according to the administration of PORT before and after PSM

Characteristics Before PSM
After PSM
PORT(−) (n=83) PORT(+) (n=143) P-value PORT(−) (n=76) PORT(+) (n=76) P-value

Race (%) White 65 (78.3) 108 (75.5) 0.621 62 (81.6) 58 (76.3) 0.726
Black 7 (8.4) 18 (12.6) 6 (7.9) 8 (10.5)
Others 11 (13.3) 17 (11.9) 8 (10.5) 10 (13.2)
Sex (%) Female 44 (53.0) 70 (49.0) 0.652 40 (52.6) 39 (51.3) 1.000
Male 39 (47.0) 73 (51.0) 36 (47.4) 37 (48.7)
Year of diagnosis (%) 1988–1999 16 (19.3) 34 (23.8) 0.719 16 (21.1) 16 (21.1) 0.655
2000–2009 41 (49.4) 65 (45.5) 36 (47.4) 31 (40.8)
2010–2015 26 (31.3) 44 (30.8) 24 (31.6) 29 (38.2)
CHSDA region (%) East 23 (27.7) 42 (29.4) 0.696 19 (25.0) 20 (26.3) 0.725
NP 12 (14.5) 24 (16.8) 38 (50.0) 33 (43.4)
PC 40 (48.2) 69 (48.3) 12 (15.8) 17 (22.4)
SW 8 (9.6) 8 (5.6) 7 (9.2) 6 (7.9)
Histology (%) SCC 16 (19.3) 48 (33.6) <0.001 16 (21.1) 14 (18.4) 0.056
ACC 22 (26.5) 63 (44.1) 22 (28.9) 36 (47.4)
Others 45 (54.2) 32 (22.4) 38 (50.0) 26 (34.2)
E stage (%) E1 59 (71.1) 74 (51.7) 0.013 52 (68.4) 49 (64.5) 0.731
E2 24 (28.9) 67 (46.9) 24 (31.6) 27 (35.5)
E3 0 (0.0) 2 (1.4) 0 0
N stage (%) N0 78 (94.0) 111 (77.6) 0.003 71 (93.4) 69 (90.8) 0.764
N1 5 (6.0) 32 (22.4) 5 (6.6) 7 (9.2)
M stage (%) M0 78 (94.0) 134 (93.7) 1.000 72 (94.7) 70 (92.1) 0.744
M1 5 (6.0) 9 (6.3) 4 (5.3) 6 (7.9)
Tumor size (%) ≤3.9 cm 51 (75.0) 99 (86.1) 0.092 47 (74.6) 52 (83.9) 0.271
>3.9 cm 17 (25.0) 16 (13.9) 16 (25.4) 10 (16.1)
Unknown 15 28 13 14
Marital status (%) No 40 (50.6) 50 (36.0) 0.049 39 (53.4) 42 (58.3) 0.617
Yes 39 (49.4) 89 (64.0) 34 (46.6) 30 (41.7)
Unknown 4 4 3 4
Age (mean [SD]) 55.07 (19.66) 56.41 (14.42) 0.559 55.75 (19.14) 56.41 (15.22) 0.815

Abbreviations: ACC, adenoid cystic carcinoma; CHSDA, Contract Health Service Delivery Areas; NP, Northern Plains; PC, Pacific Coast; PORT, postoperative radiotherapy; PSM, propensity score matching; SCC, squamous cell carcinoma; SW, Southwest.